ReviewDeutsches Arzteblatt international2025
Eosinophilic Esophagitis: Prevalence, Diagnosis, and Treatment in Childhood and Adulthood.
Review in Deutsches Arzteblatt international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- PSMB8 stratifies therapy response in eosinophilic esophagitis.Clinical and experimental immunology · 2026Article
- Food impactions in the esophagus: incidence, causes, and treatment.Zeitschrift fur Gastroenterologie · 2025Article
- [Eosinophilic esophagitis-an underestimated food allergy?]Dermatologie (Heidelberg, Germany) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEosinophilic esophagitis is a chronic, Th2 immune-mediated disease of the esophagus characterized by eso - phageal dysfunction and predominant eosinophilic inflammation. Its prevalence and incidence have risen in recent years and now stand at 16.1 per 100 000 persons and 1.7 per 100 000 persons per year.
methodsThis review is based on selected publications retrieved by a search in PubMed, Medline, and Google Scholar for clinical trials, reviews, and guidelines that were published between 2011 and 2024 in either English or German (search term, "eosinophilic esophagitis").
resultsEosinophilic esophagitis markedly impairs patients' quality of life; its diagnosis is often delayed. It can be treated with an appropriately altered diet, pharmacotherapy, and/or endoscopic intervention ("diet, drugs, dilatation"). Elimination diets with the omission of 2, 4, or 6 food groups lead to histological remission in 43%, 60%, and 79% of patients, respectively. An entirely amino acid-based diet leads to histological remission in over 90% of patients, but can only be performed for a limited time. Topical corticosteroids lead to histological remission in 60-87% of cases, proton-pump inhibitors in 30-50%, and dupilumab (anti-IL- 4Rα/IL-13Rα1) in 60-86%. These treatments differ widely in their side-effect profiles and in the restrictions they impose in everyday life, and their use must be considered individually for each patient. Because eosinophilic esophagitis is a chronic disease, remission maintenance therapy is needed over the long term.
conclusionEosinophilic esophagitis was first described three decades ago. Effective treatments are available, but questions remain concerning the longterm course of the disease, remission maintenance therapy, and non-invasive markers of disease activity, among others. Delays in diagnosis should be avoided. The appropriate treatment and long-term care of the affected patients are needed to assure them an optimal quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.